A young merchant navy officer with night sweats, fever, and weight loss

References (1)

1. Deraco M, Bartlett D, Kusamura S, Baratti D. Consensus statement on peritoneal mesothelioma. J Surg Oncol 2008; 98: 268-72. [CrossRef] 2. Kim J, Bhagwandin S, Labow DM. Malignant peritoneal mesothelioma: a review. Ann Transl Med 2017; 5: 236. [CrossRef] 3. Boffetta P. Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 2007; 18: 985-90. [CrossRef] 4. Strand LA, Martinsen JI, Koefoed VF, Sommerfelt-Pettersen J, Grimsrud TK. Asbestos-related cancers among 28,300 military servicemen in the Royal Norwegian Navy. Am J Ind Med 2010; 53: 64-71. [CrossRef] 5. Mensi C, Canti Z, Rivolta G, Riboldi L, Chiappino G. Malignant mesothelioma in the maritime professions. Med Lav 2006; 97: 82. 6. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603. [CrossRef] 7. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005; 366: 397-408. [CrossRef] 8. Alexander HR Jr, Li CY, Kennedy TJ. Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma. Ann Surg Oncol 2018; 25: 2159-64. [CrossRef] 9. Janne PA, Wozniak AJ, Belani CP, et al. Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 2005; 7: 40-6. [CrossRef]